Could SEG101 Revolutionize the Treatment for Sickle Cell Disease?
Novartis (NVS) is currently involved in developing its investigational therapy SEG101 for sickle cell disease.
If LEE011 manages to demonstrate efficacy in difficult-to-treat cancer types, it could prove to be a major competitive advantage for Novartis.
Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.
Mylan’s Key Developments and Big Plans: What You Should Know
The recent developments reported by Mylan (MYL) include commercial developments and product developments. Let’s take a closer look.
Mylan (MYL) reported an increase of 17% in revenues at ~$2.2 billion in 1Q16 from $1.9 billion in 1Q15.
The specialty segment reported an increase of 17% in revenues at $247.9 million in 1Q16 versus $211.1 million in 1Q15.
OptumRx and OptumInsight May Witness Robust Growth Trends in 2017
In 1Q17, UnitedHealth Group’s (UNH) Optum business reported $21.2 billion in revenues, which represents year-over-year growth of around 7.9%.
In 1Q17, UnitedHealth Group’s (UNH) UnitedHealthcare business witnessed a 2.5 million year-over-year increase in customers.
In 1Q17, UnitedHealth Group (UNH) witnessed a year-over-year increase of 70 basis points in its medical care ratio.
Molina Healthcare: Why Molina’s revenues have been growing fast
Molina Healthcare, Inc. (MOH): Revenue growth In general, Medicaid health plans grow revenue by increasing their membership or generating higher rates from state governments. The latter portion is often left up…
Investor day could provide a positive update to long-term growth MOH has been under pressure of late, without much reason. After beating 2Q consensus EPS estimates, even after including roughly…
Molina Healthcare, Inc. (MOH): Market overview Medicaid is a rapidly growing segment within healthcare, which should directly benefit MOH. In addition to typical market growth of mid-single digits, there are several…
Yellen’s Caution Led Battered Healthcare Up 1.2% on March 29
With the Fed stressing caution, investor sentiment turned toward the utilities and healthcare sectors, which rose 1.5% and 1.2%, respectively, on March 29.
Henry Schein reported 3Q15 net sales of $2,685.8 million, a rise of 2.4% compared to the net sales of $2,623.7 million in fiscal 3Q14.
The Health Care Select Sector SPDR ETF (XLV) has by and large been an outperformer in 2015. It has returned 5.1% on a YTD (year-to-date) basis.
How Could Trump’s Presidency Affect Hospitals and Insurance?
The effects of repealing Obamacare Donald Trump is definitely not in favor of the Affordable Care Act, known as Obamacare. As he wants to repeal the act completely and replace it…
While the recent trade cases have buoyed the US steel industry, Europe is still weak. A major recovery in U.S. Steel’s Europe earnings looks elusive in the near-term.
Wall Street analysts have projected that Universal Health Services’ net profit margin will increase marginally from 7.5% in 2015 to 7.6% in 2016.
What to Expect from Baxter International’s 1Q17 Earnings
Baxter International (BAX) has exceeded analysts’ earnings estimates for the last few quarters.
On April 26, 2017, Baxter International (BAX) will announce its 1Q17 earnings.
Baxter International (BAX) is set to release its 1Q17 results on April 26, 2017.
Analyst Ratings and Recommendations for GlaxoSmithKline
GlaxoSmithKline’s (GSK) stock price fell nearly 5.5% over the last 12 months and have risen ~5.9% in 2017 year-to-date.
The Novartis acquisition has improved sales for GSK’s Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe.
For the European markets, GSK’s revenues are expected to grow in 1Q17, mainly due to increase in sales of wellness products like Voltaren and the Sensodyne products portfolio.